论文部分内容阅读
目的探讨伴有表皮生长因子受体(EGFR)突变的肺腺癌经络氨酸激酶抑制剂(TKI)治疗后的胸部CT表现。材料与方法本回顾性研究获得机构审查委员会批准并免除知
Objective To investigate the chest computed tomography (CT) findings of tyrosine tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma associated with epidermal growth factor receptor (EGFR) mutation. Materials and Methods This retrospective study was approved by the Institutional Review Board and exempt from it